Waypoint Bio raises $20M
Waypoint Bio announced a Series A round of $20M on 1 June 2026. The company operates in HealthTech and is based in United States. It was founded by Xinchen Wang, Co-founder & CEO.
Founder
Xinchen Wang
Co-founder & CEO, Waypoint Bio
Outreach angles
- -Xinchen Wang is an MIT-trained scientist who built Waypoint Bio around in vivo spatial pooled screening for drug discovery.
- -He recruited Meta NeuroAI pioneer Patrick Kaifosh as CTO to pair AI design with cell-therapy development.
- -The $20M Series A funds Waypoint's WAY-103 program toward an investigator-initiated trial starting in late 2026.
Signals
Series AHealthcareAI-NativeDeep TechB2BRegulated Industry
Round details
Company: Waypoint Bio
Domain: waypointbio.com
Amount: $20M
Stage: Series A
Industry: HealthTech
Country: United States
Announced: 1 June 2026
Other HealthTech raises
Recently funded in United States